English

AOXING PHARMACEUTICAL COMPANY, INC.

EDGAR

Quarterly report (10-Q) · filed 2017-05-15

100 filing records in this dataset, filed from 1998-12-08 to 2017-05-15. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

5.7 million USD

2017 Q3 · USD

Exact inputs and evidence

Revenue: 5701989 USD Source

Operating margin

15.41%

2017 Q3 · %

Exact inputs and evidence

Operating Income: 878401 USD Source
Revenue: 5701989 USD Source

Operating cash flow

-3.02 million USD

2017 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -2794428 USD Source
Operating Cash Flow: 222874 USD Source

Free cash flow

-3.02 million USD

2017 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -2794428 USD Source
Operating Cash Flow: 222874 USD Source
Capital Expenditure: 8852 USD Source
Capital Expenditure: 8772 USD Source

Cash and cash equivalents: 2.74 million USD 2012-12-31 Source
Exact value

2737235 USD
Long-term debt including current maturities: Not available
Shares outstanding: 76.2 million shares 2017-03-31 Source
Exact value

76209195 shares

Reported share-count change

0.00% · 0 shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

76209195 shares · 2016-03-31· Source
76209195 shares · 2017-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

30.1 million USD

2016-04-01 – 2017-03-31

Exact inputs and evidence

Revenue: 32329525 USD · 2015-07-01 – 2016-06-30 Source
Revenue: 23504605 USD · 2015-07-01 – 2016-03-31 Source
Revenue: 7569296 USD · 2016-07-01 – 2016-09-30 Source
Revenue: 8009111 USD · 2016-10-01 – 2016-12-31 Source
Revenue: 5701989 USD · 2017-01-01 – 2017-03-31 Source

Net income

-1.42 million USD

2016-04-01 – 2017-03-31

Exact inputs and evidence

Net income: 2061224 USD · 2015-07-01 – 2016-06-30 Source
Net income: 3959293 USD · 2015-07-01 – 2016-03-31 Source
Net income: 391757 USD · 2016-07-01 – 2016-09-30 Source
Net income: -43453 USD · 2016-10-01 – 2016-12-31 Source
Net income: 132137 USD · 2017-01-01 – 2017-03-31 Source

Operating cash flow

-1.36 million USD

2016-04-01 – 2017-03-31

Exact inputs and evidence

Operating cash flow: -534990 USD · 2015-07-01 – 2016-06-30 Source
Operating cash flow: -1965846 USD · 2015-07-01 – 2016-03-31 Source
Operating cash flow: 134939 USD · 2016-07-01 – 2016-09-30 Source
Operating cash flow: 222874 USD · 2016-07-01 – 2016-12-31 Source
Operating cash flow: 134939 USD · 2016-07-01 – 2016-09-30 Source
Operating cash flow: -2794428 USD · 2016-07-01 – 2017-03-31 Source
Operating cash flow: 222874 USD · 2016-07-01 – 2016-12-31 Source

Capital expenditure

30.3 thousand USD

2016-04-01 – 2017-03-31

Exact inputs and evidence

Capital expenditure: 117862 USD · 2015-07-01 – 2016-06-30 Source
Capital expenditure: 96447 USD · 2015-07-01 – 2016-03-31 Source
Capital expenditure: 2131 USD · 2016-07-01 – 2016-09-30 Source
Capital expenditure: 8772 USD · 2016-07-01 – 2016-12-31 Source
Capital expenditure: 2131 USD · 2016-07-01 – 2016-09-30 Source
Capital expenditure: 8852 USD · 2016-07-01 – 2017-03-31 Source
Capital expenditure: 8772 USD · 2016-07-01 – 2016-12-31 Source

Free cash flow

-1.39 million USD

2016-04-01 – 2017-03-31

Exact inputs and evidence

Operating cash flow: -534990 USD · 2015-07-01 – 2016-06-30 Source
Operating cash flow: -1965846 USD · 2015-07-01 – 2016-03-31 Source
Operating cash flow: 134939 USD · 2016-07-01 – 2016-09-30 Source
Operating cash flow: 222874 USD · 2016-07-01 – 2016-12-31 Source
Operating cash flow: 134939 USD · 2016-07-01 – 2016-09-30 Source
Operating cash flow: -2794428 USD · 2016-07-01 – 2017-03-31 Source
Operating cash flow: 222874 USD · 2016-07-01 – 2016-12-31 Source
Capital expenditure: 117862 USD · 2015-07-01 – 2016-06-30 Source
Capital expenditure: 96447 USD · 2015-07-01 – 2016-03-31 Source
Capital expenditure: 2131 USD · 2016-07-01 – 2016-09-30 Source
Capital expenditure: 8772 USD · 2016-07-01 – 2016-12-31 Source
Capital expenditure: 2131 USD · 2016-07-01 – 2016-09-30 Source
Capital expenditure: 8852 USD · 2016-07-01 – 2017-03-31 Source
Capital expenditure: 8772 USD · 2016-07-01 – 2016-12-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2017-05-15.

Financial data available through: 2016-06-30.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2016-06-30
Operating income: 11 of 11 periods available· newest 2016-06-30
Net income: 10 of 11 periods available· newest 2016-06-30
Operating cash flow: 11 of 11 periods available· newest 2016-06-30
Capital expenditure: 11 of 11 periods available· newest 2016-06-30
Total assets: 11 of 11 periods available· newest 2016-06-30
Total liabilities: 2 of 11 periods available· newest 2007-06-30
Current assets: 11 of 11 periods available· newest 2016-06-30
Current liabilities: 11 of 11 periods available· newest 2016-06-30
Cash and cash equivalents: 7 of 11 periods available· newest 2012-06-30
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2016-06-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+26.9%

Prior period

USD 25.48 million

2014-07-01 – 2015-06-30
Current period

USD 32.33 million

2015-07-01 – 2016-06-30

Exact inputs and evidence

32329525 − 25481199 = 6848326 USD

25481199 USD · 2014-07-01 – 2015-06-30
Inspect prior input Prior source
32329525 USD · 2015-07-01 – 2016-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · AOXING PHARMACEUTICAL COMPANY, INC. · 2016-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Year-over-year change in Revenue: 6848326 USD Concept: fundies:Revenue Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 32329525 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#6246 Filing: 000109690616001934 Input fundies:Revenue: 25481199 USD (2014-07-01 to 2015-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#6364 Filing: 000109690616001934
The citation records this snapshot. The page link may show a newer release later.
Net income
-62.5%

Prior period

USD 5.49 million

2014-07-01 – 2015-06-30
Current period

USD 2.06 million

2015-07-01 – 2016-06-30

Exact inputs and evidence

2061224 − 5494713 = -3433489 USD

5494713 USD · 2014-07-01 – 2015-06-30
Inspect prior input Prior source
2061224 USD · 2015-07-01 – 2016-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · AOXING PHARMACEUTICAL COMPANY, INC. · 2016-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Year-over-year change in Net income: -3433489 USD Concept: fundies:NetIncome Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 2061224 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#34301 Filing: 000109690616001934 Input fundies:NetIncome: 5494713 USD (2014-07-01 to 2015-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#34414 Filing: 000109690616001934
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-117.7%

Prior period

USD 3.03 million

2014-07-01 – 2015-06-30
Current period

−USD 534,990

2015-07-01 – 2016-06-30

Exact inputs and evidence

-534990 − 3025739 = -3560729 USD

3025739 USD · 2014-07-01 – 2015-06-30
Inspect prior input Prior source
-534990 USD · 2015-07-01 – 2016-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2016-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Year-over-year change in Operating cash flow: -3560729 USD Concept: fundies:OperatingCashFlow Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -534990 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#37997 Filing: 000109690616001934 Input fundies:OperatingCashFlow: 3025739 USD (2014-07-01 to 2015-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#38168 Filing: 000109690616001934
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-95.6%

Prior period

USD 2.71 million

2014-07-01 – 2015-06-30
Current period

USD 117,862

2015-07-01 – 2016-06-30

Exact inputs and evidence

117862 − 2705298 = -2587436 USD

2705298 USD · 2014-07-01 – 2015-06-30
Inspect prior input Prior source
117862 USD · 2015-07-01 – 2016-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · AOXING PHARMACEUTICAL COMPANY, INC. · 2016-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Year-over-year change in Capital expenditure: -2587436 USD Concept: fundies:CapitalExpenditure Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 117862 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#38339 Filing: 000109690616001934 Input fundies:CapitalExpenditure: 2705298 USD (2014-07-01 to 2015-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#38509 Filing: 000109690616001934
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2016 2015-07-01 – 2016-06-30

Revenue USD 32.33 million 100% of revenue
Cost of revenue USD 7.78 million 24% of revenue
Operating expenses USD 18.33 million 57% of revenue
Operating income USD 6.23 million 19% of revenue
Tax, interest and other Derived USD 4.17 million 13% of revenue
Net income USD 2.06 million 6.4% of revenue

Cash

Operating cash flow −USD 534,990 −1.7% of revenue
Capital expenditure USD 117,862 0.4% of revenue
Free cash flow Derived −USD 652,852 −2% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2007 Operating loss: operating costs were 173% of revenue.
2008 Operating loss: operating costs were 151% of revenue.
2009 Operating loss: operating costs were 171% of revenue.
2010 Not shown: operating income or net income is not reported.
2011 Operating loss: operating costs were 173% of revenue.
2012 Operating loss: operating costs were 279% of revenue.
2013 Operating loss: operating costs were 231% of revenue.
2014 Operating loss: operating costs were 126% of revenue.
2015 22%13%66%
2016 13%81%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2007 2006-07-01 – 2007-06-30	1938639	3346125 Derived	-1407486	12806145 Derived	-14213631	-2168847 Derived	Source 2006-07-01 – 2007-06-30: 1938639 USD Inspect Revenue Open source 2006-07-01 – 2007-06-30: -1407486 USD Inspect Operating Income Open source 2006-07-01 – 2007-06-30: -14213631 USD Inspect Net Income Open source 2006-07-01 – 2007-06-30: -1062573 USD Inspect Operating Cash Flow Open source 2006-07-01 – 2007-06-30: 1106274 USD Inspect Capital Expenditure Open source
2008 2007-07-01 – 2008-06-30	7065015	10643981 Derived	-3578966	-7225825 Derived	3646859	-2464436 Derived	Source 2007-07-01 – 2008-06-30: 7065015 USD Inspect Revenue Open source 2007-07-01 – 2008-06-30: -3578966 USD Inspect Operating Income Open source 2007-07-01 – 2008-06-30: 3646859 USD Inspect Net Income Open source 2007-07-01 – 2008-06-30: -980947 USD Inspect Operating Cash Flow Open source 2007-07-01 – 2008-06-30: 1483489 USD Inspect Capital Expenditure Open source
2009 2008-07-01 – 2009-06-30	8941907	15290392 Derived	-6348485	-3653435 Derived	-2695050	-2869907 Derived	Source 2008-07-01 – 2009-06-30: 8941907 USD Inspect Revenue Open source 2008-07-01 – 2009-06-30: -6348485 USD Inspect Operating Income Open source 2008-07-01 – 2009-06-30: -2695050 USD Inspect Net Income Open source 2008-07-01 – 2009-06-30: -642598 USD Inspect Operating Cash Flow Open source 2008-07-01 – 2009-06-30: 2227309 USD Inspect Capital Expenditure Open source
2010 2009-07-01 – 2010-06-30	6115774	9699912 Derived	-3584138	Unavailable	Unavailable	-5974736 Derived	Source 2009-07-01 – 2010-06-30: 6115774 USD Inspect Revenue Open source 2009-07-01 – 2010-06-30: -3584138 USD Inspect Operating Income Open source 2009-07-01 – 2010-06-30: -3978718 USD Inspect Operating Cash Flow Open source 2009-07-01 – 2010-06-30: 1996018 USD Inspect Capital Expenditure Open source
2011 2010-07-01 – 2011-06-30	6651048	11506186 Derived	-4855138	2555710 Derived	-7410848	-4046297 Derived	Source 2010-07-01 – 2011-06-30: 6651048 USD Inspect Revenue Open source 2010-07-01 – 2011-06-30: -4855138 USD Inspect Operating Income Open source 2010-07-01 – 2011-06-30: -7410848 USD Inspect Net Income Open source 2010-07-01 – 2011-06-30: -2673141 USD Inspect Operating Cash Flow Open source 2010-07-01 – 2011-06-30: 1373156 USD Inspect Capital Expenditure Open source
2012 2011-07-01 – 2012-06-30	8134077	22682601 Derived	-14548524	1271796 Derived	-15820320	-2078576 Derived	Source 2011-07-01 – 2012-06-30: 8134077 USD Inspect Revenue Open source 2011-07-01 – 2012-06-30: -14548524 USD Inspect Operating Income Open source 2011-07-01 – 2012-06-30: -15820320 USD Inspect Net Income Open source 2011-07-01 – 2012-06-30: -1326190 USD Inspect Operating Cash Flow Open source 2011-07-01 – 2012-06-30: 752386 USD Inspect Capital Expenditure Open source
2013 2012-07-01 – 2013-06-30	10829839	25051284 Derived	-14221445	3069173 Derived	-17290618	-8756527 Derived	Source 2012-07-01 – 2013-06-30: 10829839 USD Inspect Revenue Open source 2012-07-01 – 2013-06-30: -14221445 USD Inspect Operating Income Open source 2012-07-01 – 2013-06-30: -17290618 USD Inspect Net Income Open source 2012-07-01 – 2013-06-30: -8317173 USD Inspect Operating Cash Flow Open source 2012-07-01 – 2013-06-30: 439354 USD Inspect Capital Expenditure Open source
2014 2013-07-01 – 2014-06-30	12739371	16074250 Derived	-3334879	5299501 Derived	-8634380	-7998899 Derived	Source 2013-07-01 – 2014-06-30: 12739371 USD Inspect Revenue Open source 2013-07-01 – 2014-06-30: -3334879 USD Inspect Operating Income Open source 2013-07-01 – 2014-06-30: -8634380 USD Inspect Net Income Open source 2013-07-01 – 2014-06-30: -7729977 USD Inspect Operating Cash Flow Open source 2013-07-01 – 2014-06-30: 268922 USD Inspect Capital Expenditure Open source
2015 2014-07-01 – 2015-06-30	25481199	16785542 Derived	8695657	3200944 Derived	5494713	320441 Derived	Source 2014-07-01 – 2015-06-30: 25481199 USD Inspect Revenue Open source 2014-07-01 – 2015-06-30: 8695657 USD Inspect Operating Income Open source 2014-07-01 – 2015-06-30: 5494713 USD Inspect Net Income Open source 2014-07-01 – 2015-06-30: 3025739 USD Inspect Operating Cash Flow Open source 2014-07-01 – 2015-06-30: 2705298 USD Inspect Capital Expenditure Open source
2016 2015-07-01 – 2016-06-30	32329525	26101474 Derived	6228051	4166827 Derived	2061224	-652852 Derived	Source 2015-07-01 – 2016-06-30: 32329525 USD Inspect Revenue Open source 2015-07-01 – 2016-06-30: 6228051 USD Inspect Operating Income Open source 2015-07-01 – 2016-06-30: 2061224 USD Inspect Net Income Open source 2015-07-01 – 2016-06-30: -534990 USD Inspect Operating Cash Flow Open source 2015-07-01 – 2016-06-30: 117862 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 32.3M 2016

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20072007-06-30	Revenue	1938639	Revenue: 1938639 Open source
20082008-06-30	Revenue	7065015	Revenue: 7065015 Open source
20092009-06-30	Revenue	8941907	Revenue: 8941907 Open source
20102010-06-30	Revenue	6115774	Revenue: 6115774 Open source
20112011-06-30	Revenue	6651048	Revenue: 6651048 Open source
20122012-06-30	Revenue	8134077	Revenue: 8134077 Open source
20132013-06-30	Revenue	10829839	Revenue: 10829839 Open source
20142014-06-30	Revenue	12739371	Revenue: 12739371 Open source
20152015-06-30	Revenue	25481199	Revenue: 25481199 Open source
20162016-06-30	Revenue	32329525	Revenue: 32329525 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

26.9% 2016

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20072007-06-30	Year over year	No prior comparable period	Revenue: 1938639 Open source Revenue: 0 Open source
20082008-06-30	Year over year	264.4%	Revenue: 7065015 Open source Revenue: 1938639 Open source
20092009-06-30	Year over year	26.6%	Revenue: 8941907 Open source Revenue: 7065015 Open source
20102010-06-30	Year over year	-31.6%	Revenue: 6115774 Open source Revenue: 8941907 Open source
20112011-06-30	Year over year	8.8%	Revenue: 6651048 Open source Revenue: 6115774 Open source
20122012-06-30	Year over year	22.3%	Revenue: 8134077 Open source Revenue: 6651048 Open source
20132013-06-30	Year over year	33.1%	Revenue: 10829839 Open source Revenue: 8134077 Open source
20142014-06-30	Year over year	17.6%	Revenue: 12739371 Open source Revenue: 10829839 Open source
20152015-06-30	Year over year	100%	Revenue: 25481199 Open source Revenue: 12739371 Open source
20162016-06-30	Year over year	26.9%	Revenue: 32329525 Open source Revenue: 25481199 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 19.3% 2016

Net margin 6.4% 2016

Free cash flow margin -2% 2016

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20072007-06-30	Operating margin	-72.6%	Operating Income: -1407486 Open source Revenue: 1938639 Open source
20082008-06-30	Operating margin	-50.7%	Operating Income: -3578966 Open source Revenue: 7065015 Open source
20092009-06-30	Operating margin	-71%	Operating Income: -6348485 Open source Revenue: 8941907 Open source
20102010-06-30	Operating margin	-58.6%	Operating Income: -3584138 Open source Revenue: 6115774 Open source
20112011-06-30	Operating margin	-73%	Operating Income: -4855138 Open source Revenue: 6651048 Open source
20122012-06-30	Operating margin	-178.9%	Operating Income: -14548524 Open source Revenue: 8134077 Open source
20132013-06-30	Operating margin	-131.3%	Operating Income: -14221445 Open source Revenue: 10829839 Open source
20142014-06-30	Operating margin	-26.2%	Operating Income: -3334879 Open source Revenue: 12739371 Open source
20152015-06-30	Operating margin	34.1%	Operating Income: 8695657 Open source Revenue: 25481199 Open source
20162016-06-30	Operating margin	19.3%	Operating Income: 6228051 Open source Revenue: 32329525 Open source
20072007-06-30	Net margin	-733.2%	Net Income: -14213631 Open source Revenue: 1938639 Open source
20082008-06-30	Net margin	51.6%	Net Income: 3646859 Open source Revenue: 7065015 Open source
20092009-06-30	Net margin	-30.1%	Net Income: -2695050 Open source Revenue: 8941907 Open source
2010-06-30	Net margin	Not reported	Revenue: 6115774 Open source
20112011-06-30	Net margin	-111.4%	Net Income: -7410848 Open source Revenue: 6651048 Open source
20122012-06-30	Net margin	-194.5%	Net Income: -15820320 Open source Revenue: 8134077 Open source
20132013-06-30	Net margin	-159.7%	Net Income: -17290618 Open source Revenue: 10829839 Open source
20142014-06-30	Net margin	-67.8%	Net Income: -8634380 Open source Revenue: 12739371 Open source
20152015-06-30	Net margin	21.6%	Net Income: 5494713 Open source Revenue: 25481199 Open source
20162016-06-30	Net margin	6.4%	Net Income: 2061224 Open source Revenue: 32329525 Open source
20072007-06-30	Free cash flow margin	-111.9%	Revenue: 1938639 Open source Operating Cash Flow: -1062573 Open source Capital Expenditure: 1106274 Open source
20082008-06-30	Free cash flow margin	-34.9%	Revenue: 7065015 Open source Operating Cash Flow: -980947 Open source Capital Expenditure: 1483489 Open source
20092009-06-30	Free cash flow margin	-32.1%	Revenue: 8941907 Open source Operating Cash Flow: -642598 Open source Capital Expenditure: 2227309 Open source
20102010-06-30	Free cash flow margin	-97.7%	Revenue: 6115774 Open source Operating Cash Flow: -3978718 Open source Capital Expenditure: 1996018 Open source
20112011-06-30	Free cash flow margin	-60.8%	Revenue: 6651048 Open source Operating Cash Flow: -2673141 Open source Capital Expenditure: 1373156 Open source
20122012-06-30	Free cash flow margin	-25.6%	Revenue: 8134077 Open source Operating Cash Flow: -1326190 Open source Capital Expenditure: 752386 Open source
20132013-06-30	Free cash flow margin	-80.9%	Revenue: 10829839 Open source Operating Cash Flow: -8317173 Open source Capital Expenditure: 439354 Open source
20142014-06-30	Free cash flow margin	-62.8%	Revenue: 12739371 Open source Operating Cash Flow: -7729977 Open source Capital Expenditure: 268922 Open source
20152015-06-30	Free cash flow margin	1.3%	Revenue: 25481199 Open source Operating Cash Flow: 3025739 Open source Capital Expenditure: 2705298 Open source
20162016-06-30	Free cash flow margin	-2%	Revenue: 32329525 Open source Operating Cash Flow: -534990 Open source Capital Expenditure: 117862 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -535K 2016

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20072007-06-30	Operating cash flow	-1062573	Operating Cash Flow: -1062573 Open source
20082008-06-30	Operating cash flow	-980947	Operating Cash Flow: -980947 Open source
20092009-06-30	Operating cash flow	-642598	Operating Cash Flow: -642598 Open source
20102010-06-30	Operating cash flow	-3978718	Operating Cash Flow: -3978718 Open source
20112011-06-30	Operating cash flow	-2673141	Operating Cash Flow: -2673141 Open source
20122012-06-30	Operating cash flow	-1326190	Operating Cash Flow: -1326190 Open source
20132013-06-30	Operating cash flow	-8317173	Operating Cash Flow: -8317173 Open source
20142014-06-30	Operating cash flow	-7729977	Operating Cash Flow: -7729977 Open source
20152015-06-30	Operating cash flow	3025739	Operating Cash Flow: 3025739 Open source
20162016-06-30	Operating cash flow	-534990	Operating Cash Flow: -534990 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -652.9K 2016

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20072007-06-30	Free cash flow	-2168847	Operating Cash Flow: -1062573 Open source Capital Expenditure: 1106274 Open source
20082008-06-30	Free cash flow	-2464436	Operating Cash Flow: -980947 Open source Capital Expenditure: 1483489 Open source
20092009-06-30	Free cash flow	-2869907	Operating Cash Flow: -642598 Open source Capital Expenditure: 2227309 Open source
20102010-06-30	Free cash flow	-5974736	Operating Cash Flow: -3978718 Open source Capital Expenditure: 1996018 Open source
20112011-06-30	Free cash flow	-4046297	Operating Cash Flow: -2673141 Open source Capital Expenditure: 1373156 Open source
20122012-06-30	Free cash flow	-2078576	Operating Cash Flow: -1326190 Open source Capital Expenditure: 752386 Open source
20132013-06-30	Free cash flow	-8756527	Operating Cash Flow: -8317173 Open source Capital Expenditure: 439354 Open source
20142014-06-30	Free cash flow	-7998899	Operating Cash Flow: -7729977 Open source Capital Expenditure: 268922 Open source
20152015-06-30	Free cash flow	320441	Operating Cash Flow: 3025739 Open source Capital Expenditure: 2705298 Open source
20162016-06-30	Free cash flow	-652852	Operating Cash Flow: -534990 Open source Capital Expenditure: 117862 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

145.1% 2007

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20072007-06-30	Liabilities / assets	145.1%	Total Liabilities: 30724778 Open source Total Assets: 21179618 Open source
2008-06-30	Liabilities / assets	Not reported	Total Assets: 56125090 Open source
2009-06-30	Liabilities / assets	Not reported	Total Assets: 56744484 Open source
2010-06-30	Liabilities / assets	Not reported	Total Assets: 58327494 Open source
2011-06-30	Liabilities / assets	Not reported	Total Assets: 55873724 Open source
2012-06-30	Liabilities / assets	Not reported	Total Assets: 45089721 Open source
2013-06-30	Liabilities / assets	Not reported	Total Assets: 39732880 Open source
2014-06-30	Liabilities / assets	Not reported	Total Assets: 39732880 Open source
2015-06-30	Liabilities / assets	Not reported	Total Assets: 53040692 Open source
2016-06-30	Liabilities / assets	Not reported	Total Assets: 56231591 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.71× 2016

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20072007-06-30	Current assets / current liabilities	0.17×	Current Assets: 1961031 Open source Current Liabilities: 11603564 Open source
20082008-06-30	Current assets / current liabilities	0.28×	Current Assets: 5253727 Open source Current Liabilities: 18476086 Open source
20092009-06-30	Current assets / current liabilities	0.17×	Current Assets: 3613053 Open source Current Liabilities: 21141066 Open source
20102010-06-30	Current assets / current liabilities	0.66×	Current Assets: 8920106 Open source Current Liabilities: 13555593 Open source
20112011-06-30	Current assets / current liabilities	0.5×	Current Assets: 7378195 Open source Current Liabilities: 14635762 Open source
20122012-06-30	Current assets / current liabilities	0.51×	Current Assets: 9521816 Open source Current Liabilities: 18634658 Open source
20132013-06-30	Current assets / current liabilities	0.55×	Current Assets: 11892194 Open source Current Liabilities: 21703504 Open source
20142014-06-30	Current assets / current liabilities	0.32×	Current Assets: 10920613 Open source Current Liabilities: 34214799 Open source
20152015-06-30	Current assets / current liabilities	0.51×	Current Assets: 21096033 Open source Current Liabilities: 41239662 Open source
20162016-06-30	Current assets / current liabilities	0.71×	Current Assets: 26866763 Open source Current Liabilities: 37815530 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2007 2006-07-01 – 2007-06-30	−USD 14.21 million Exact value Exact value: -14213631 USD 2006-07-01 – 2007-06-30: -14213631 USD Inspect Net Income Open source Share or cite Citation for Net Income · AOXING PHARMACEUTICAL COMPANY, INC. · 2007-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Net Income: -14213631 USD Concept: fundies:NetIncome Period: 2006-07-01 to 2007-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ANetIncome&period=2007-06-30&surface=latest&period_type=duration&start=2006-07-01&unit=USD&dimensions= Input fundies:NetIncome: -14213631 USD (2006-07-01 to 2007-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-09-001139.txt#5210 The citation records this snapshot. The page link may show a newer release later.	−USD 1.06 million Exact value Exact value: -1062573 USD 2006-07-01 – 2007-06-30: -1062573 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2007-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Operating Cash Flow: -1062573 USD Concept: fundies:OperatingCashFlow Period: 2006-07-01 to 2007-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3AOperatingCashFlow&period=2007-06-30&surface=latest&period_type=duration&start=2006-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1062573 USD (2006-07-01 to 2007-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-08-001895.txt#7637 The citation records this snapshot. The page link may show a newer release later.	USD 1.11 million Exact value Exact value: 1106274 USD 2006-07-01 – 2007-06-30: 1106274 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AOXING PHARMACEUTICAL COMPANY, INC. · 2007-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Capital Expenditure: 1106274 USD Concept: fundies:CapitalExpenditure Period: 2006-07-01 to 2007-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ACapitalExpenditure&period=2007-06-30&surface=latest&period_type=duration&start=2006-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1106274 USD (2006-07-01 to 2007-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-08-001895.txt#7677 The citation records this snapshot. The page link may show a newer release later.	−USD 2.17 million Calculation and evidence -1062573 − 1106274 USD Exact free cash flow: -2168847 USD 2006-07-01 – 2007-06-30: -1062573 USD · Inspect Operating Cash Flow · Source 2006-07-01 – 2007-06-30: 1106274 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2007-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Free cash flow: -2168847 USD Concept: free-cash-flow Period: 2006-07-01 to 2007-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1062573 USD (2006-07-01 to 2007-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-08-001895.txt#7637 Input fundies:CapitalExpenditure: 1106274 USD (2006-07-01 to 2007-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-08-001895.txt#7677 The citation records this snapshot. The page link may show a newer release later.
2008 2007-07-01 – 2008-06-30	USD 3.65 million Exact value Exact value: 3646859 USD 2007-07-01 – 2008-06-30: 3646859 USD Inspect Net Income Open source Share or cite Citation for Net Income · AOXING PHARMACEUTICAL COMPANY, INC. · 2008-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Net Income: 3646859 USD Concept: fundies:NetIncome Period: 2007-07-01 to 2008-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ANetIncome&period=2008-06-30&surface=latest&period_type=duration&start=2007-07-01&unit=USD&dimensions= Input fundies:NetIncome: 3646859 USD (2007-07-01 to 2008-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-10-000296.txt#5815 The citation records this snapshot. The page link may show a newer release later.	−USD 980,947 Exact value Exact value: -980947 USD 2007-07-01 – 2008-06-30: -980947 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2008-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Operating Cash Flow: -980947 USD Concept: fundies:OperatingCashFlow Period: 2007-07-01 to 2008-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3AOperatingCashFlow&period=2008-06-30&surface=latest&period_type=duration&start=2007-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -980947 USD (2007-07-01 to 2008-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-10-000296.txt#6037 The citation records this snapshot. The page link may show a newer release later.	USD 1.48 million Exact value Exact value: 1483489 USD 2007-07-01 – 2008-06-30: 1483489 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AOXING PHARMACEUTICAL COMPANY, INC. · 2008-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Capital Expenditure: 1483489 USD Concept: fundies:CapitalExpenditure Period: 2007-07-01 to 2008-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ACapitalExpenditure&period=2008-06-30&surface=latest&period_type=duration&start=2007-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1483489 USD (2007-07-01 to 2008-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-10-000296.txt#6074 The citation records this snapshot. The page link may show a newer release later.	−USD 2.46 million Calculation and evidence -980947 − 1483489 USD Exact free cash flow: -2464436 USD 2007-07-01 – 2008-06-30: -980947 USD · Inspect Operating Cash Flow · Source 2007-07-01 – 2008-06-30: 1483489 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2008-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Free cash flow: -2464436 USD Concept: free-cash-flow Period: 2007-07-01 to 2008-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -980947 USD (2007-07-01 to 2008-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-10-000296.txt#6037 Input fundies:CapitalExpenditure: 1483489 USD (2007-07-01 to 2008-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-10-000296.txt#6074 The citation records this snapshot. The page link may show a newer release later.
2009 2008-07-01 – 2009-06-30	−USD 2.7 million Exact value Exact value: -2695050 USD 2008-07-01 – 2009-06-30: -2695050 USD Inspect Net Income Open source Share or cite Citation for Net Income · AOXING PHARMACEUTICAL COMPANY, INC. · 2009-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Net Income: -2695050 USD Concept: fundies:NetIncome Period: 2008-07-01 to 2009-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ANetIncome&period=2009-06-30&surface=latest&period_type=duration&start=2008-07-01&unit=USD&dimensions= Input fundies:NetIncome: -2695050 USD (2008-07-01 to 2009-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-10-000296.txt#5815 The citation records this snapshot. The page link may show a newer release later.	−USD 642,598 Exact value Exact value: -642598 USD 2008-07-01 – 2009-06-30: -642598 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2009-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Operating Cash Flow: -642598 USD Concept: fundies:OperatingCashFlow Period: 2008-07-01 to 2009-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3AOperatingCashFlow&period=2009-06-30&surface=latest&period_type=duration&start=2008-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -642598 USD (2008-07-01 to 2009-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-10-000296.txt#6037 The citation records this snapshot. The page link may show a newer release later.	USD 2.23 million Exact value Exact value: 2227309 USD 2008-07-01 – 2009-06-30: 2227309 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AOXING PHARMACEUTICAL COMPANY, INC. · 2009-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Capital Expenditure: 2227309 USD Concept: fundies:CapitalExpenditure Period: 2008-07-01 to 2009-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ACapitalExpenditure&period=2009-06-30&surface=latest&period_type=duration&start=2008-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2227309 USD (2008-07-01 to 2009-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-10-000296.txt#6074 The citation records this snapshot. The page link may show a newer release later.	−USD 2.87 million Calculation and evidence -642598 − 2227309 USD Exact free cash flow: -2869907 USD 2008-07-01 – 2009-06-30: -642598 USD · Inspect Operating Cash Flow · Source 2008-07-01 – 2009-06-30: 2227309 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2009-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Free cash flow: -2869907 USD Concept: free-cash-flow Period: 2008-07-01 to 2009-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -642598 USD (2008-07-01 to 2009-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-10-000296.txt#6037 Input fundies:CapitalExpenditure: 2227309 USD (2008-07-01 to 2009-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-10-000296.txt#6074 The citation records this snapshot. The page link may show a newer release later.
2010 2009-07-01 – 2010-06-30	Unavailable Not reported for this period.	−USD 3.98 million Exact value Exact value: -3978718 USD 2009-07-01 – 2010-06-30: -3978718 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2010-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Operating Cash Flow: -3978718 USD Concept: fundies:OperatingCashFlow Period: 2009-07-01 to 2010-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3AOperatingCashFlow&period=2010-06-30&surface=latest&period_type=duration&start=2009-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3978718 USD (2009-07-01 to 2010-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-11-002277.txt#4895 The citation records this snapshot. The page link may show a newer release later.	USD 2 million Exact value Exact value: 1996018 USD 2009-07-01 – 2010-06-30: 1996018 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AOXING PHARMACEUTICAL COMPANY, INC. · 2010-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Capital Expenditure: 1996018 USD Concept: fundies:CapitalExpenditure Period: 2009-07-01 to 2010-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ACapitalExpenditure&period=2010-06-30&surface=latest&period_type=duration&start=2009-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1996018 USD (2009-07-01 to 2010-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-11-002277.txt#4929 The citation records this snapshot. The page link may show a newer release later.	−USD 5.97 million Calculation and evidence -3978718 − 1996018 USD Exact free cash flow: -5974736 USD 2009-07-01 – 2010-06-30: -3978718 USD · Inspect Operating Cash Flow · Source 2009-07-01 – 2010-06-30: 1996018 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2010-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Free cash flow: -5974736 USD Concept: free-cash-flow Period: 2009-07-01 to 2010-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3978718 USD (2009-07-01 to 2010-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-11-002277.txt#4895 Input fundies:CapitalExpenditure: 1996018 USD (2009-07-01 to 2010-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/0001096906-11-002277.txt#4929 The citation records this snapshot. The page link may show a newer release later.
2011 2010-07-01 – 2011-06-30	−USD 7.41 million Exact value Exact value: -7410848 USD 2010-07-01 – 2011-06-30: -7410848 USD Inspect Net Income Open source Share or cite Citation for Net Income · AOXING PHARMACEUTICAL COMPANY, INC. · 2011-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Net Income: -7410848 USD Concept: fundies:NetIncome Period: 2010-07-01 to 2011-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ANetIncome&period=2011-06-30&surface=latest&period_type=duration&start=2010-07-01&unit=USD&dimensions= Input fundies:NetIncome: -7410848 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690612002536/axn-20120630.xml#429310 Filing: 000109690612002536 The citation records this snapshot. The page link may show a newer release later.	−USD 2.67 million Exact value Exact value: -2673141 USD 2010-07-01 – 2011-06-30: -2673141 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2011-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Operating Cash Flow: -2673141 USD Concept: fundies:OperatingCashFlow Period: 2010-07-01 to 2011-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3AOperatingCashFlow&period=2011-06-30&surface=latest&period_type=duration&start=2010-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2673141 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690612002536/axn-20120630.xml#433828 Filing: 000109690612002536 The citation records this snapshot. The page link may show a newer release later.	USD 1.37 million Exact value Exact value: 1373156 USD 2010-07-01 – 2011-06-30: 1373156 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AOXING PHARMACEUTICAL COMPANY, INC. · 2011-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Capital Expenditure: 1373156 USD Concept: fundies:CapitalExpenditure Period: 2010-07-01 to 2011-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ACapitalExpenditure&period=2011-06-30&surface=latest&period_type=duration&start=2010-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1373156 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690612002536/axn-20120630.xml#434170 Filing: 000109690612002536 The citation records this snapshot. The page link may show a newer release later.	−USD 4.05 million Calculation and evidence -2673141 − 1373156 USD Exact free cash flow: -4046297 USD 2010-07-01 – 2011-06-30: -2673141 USD · Inspect Operating Cash Flow · Source 2010-07-01 – 2011-06-30: 1373156 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2011-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Free cash flow: -4046297 USD Concept: free-cash-flow Period: 2010-07-01 to 2011-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2673141 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690612002536/axn-20120630.xml#433828 Filing: 000109690612002536 Input fundies:CapitalExpenditure: 1373156 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690612002536/axn-20120630.xml#434170 Filing: 000109690612002536 The citation records this snapshot. The page link may show a newer release later.
2012 2011-07-01 – 2012-06-30	−USD 15.82 million Exact value Exact value: -15820320 USD 2011-07-01 – 2012-06-30: -15820320 USD Inspect Net Income Open source Share or cite Citation for Net Income · AOXING PHARMACEUTICAL COMPANY, INC. · 2012-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Net Income: -15820320 USD Concept: fundies:NetIncome Period: 2011-07-01 to 2012-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ANetIncome&period=2012-06-30&surface=latest&period_type=duration&start=2011-07-01&unit=USD&dimensions= Input fundies:NetIncome: -15820320 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690613001576/axn-20130630.xml#33165 Filing: 000109690613001576 The citation records this snapshot. The page link may show a newer release later.	−USD 1.33 million Exact value Exact value: -1326190 USD 2011-07-01 – 2012-06-30: -1326190 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2012-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Operating Cash Flow: -1326190 USD Concept: fundies:OperatingCashFlow Period: 2011-07-01 to 2012-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3AOperatingCashFlow&period=2012-06-30&surface=latest&period_type=duration&start=2011-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1326190 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690613001576/axn-20130630.xml#24590 Filing: 000109690613001576 The citation records this snapshot. The page link may show a newer release later.	USD 752,386 Exact value Exact value: 752386 USD 2011-07-01 – 2012-06-30: 752386 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AOXING PHARMACEUTICAL COMPANY, INC. · 2012-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Capital Expenditure: 752386 USD Concept: fundies:CapitalExpenditure Period: 2011-07-01 to 2012-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ACapitalExpenditure&period=2012-06-30&surface=latest&period_type=duration&start=2011-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 752386 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690613001576/axn-20130630.xml#24932 Filing: 000109690613001576 The citation records this snapshot. The page link may show a newer release later.	−USD 2.08 million Calculation and evidence -1326190 − 752386 USD Exact free cash flow: -2078576 USD 2011-07-01 – 2012-06-30: -1326190 USD · Inspect Operating Cash Flow · Source 2011-07-01 – 2012-06-30: 752386 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2012-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Free cash flow: -2078576 USD Concept: free-cash-flow Period: 2011-07-01 to 2012-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1326190 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690613001576/axn-20130630.xml#24590 Filing: 000109690613001576 Input fundies:CapitalExpenditure: 752386 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690613001576/axn-20130630.xml#24932 Filing: 000109690613001576 The citation records this snapshot. The page link may show a newer release later.
2013 2012-07-01 – 2013-06-30	−USD 17.29 million Exact value Exact value: -17290618 USD 2012-07-01 – 2013-06-30: -17290618 USD Inspect Net Income Open source Share or cite Citation for Net Income · AOXING PHARMACEUTICAL COMPANY, INC. · 2013-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Net Income: -17290618 USD Concept: fundies:NetIncome Period: 2012-07-01 to 2013-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ANetIncome&period=2013-06-30&surface=latest&period_type=duration&start=2012-07-01&unit=USD&dimensions= Input fundies:NetIncome: -17290618 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690614001354/axn-20140630.xml#19353 Filing: 000109690614001354 The citation records this snapshot. The page link may show a newer release later.	−USD 8.32 million Exact value Exact value: -8317173 USD 2012-07-01 – 2013-06-30: -8317173 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2013-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Operating Cash Flow: -8317173 USD Concept: fundies:OperatingCashFlow Period: 2012-07-01 to 2013-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3AOperatingCashFlow&period=2013-06-30&surface=latest&period_type=duration&start=2012-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8317173 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690614001354/axn-20140630.xml#30758 Filing: 000109690614001354 The citation records this snapshot. The page link may show a newer release later.	USD 439,354 Exact value Exact value: 439354 USD 2012-07-01 – 2013-06-30: 439354 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AOXING PHARMACEUTICAL COMPANY, INC. · 2013-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Capital Expenditure: 439354 USD Concept: fundies:CapitalExpenditure Period: 2012-07-01 to 2013-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ACapitalExpenditure&period=2013-06-30&surface=latest&period_type=duration&start=2012-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 439354 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690614001354/axn-20140630.xml#31100 Filing: 000109690614001354 The citation records this snapshot. The page link may show a newer release later.	−USD 8.76 million Calculation and evidence -8317173 − 439354 USD Exact free cash flow: -8756527 USD 2012-07-01 – 2013-06-30: -8317173 USD · Inspect Operating Cash Flow · Source 2012-07-01 – 2013-06-30: 439354 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2013-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Free cash flow: -8756527 USD Concept: free-cash-flow Period: 2012-07-01 to 2013-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8317173 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690614001354/axn-20140630.xml#30758 Filing: 000109690614001354 Input fundies:CapitalExpenditure: 439354 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690614001354/axn-20140630.xml#31100 Filing: 000109690614001354 The citation records this snapshot. The page link may show a newer release later.
2014 2013-07-01 – 2014-06-30	−USD 8.63 million Exact value Exact value: -8634380 USD 2013-07-01 – 2014-06-30: -8634380 USD Inspect Net Income Open source Share or cite Citation for Net Income · AOXING PHARMACEUTICAL COMPANY, INC. · 2014-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Net Income: -8634380 USD Concept: fundies:NetIncome Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ANetIncome&period=2014-06-30&surface=latest&period_type=duration&start=2013-07-01&unit=USD&dimensions= Input fundies:NetIncome: -8634380 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690615001048/axn-20150630.xml#20184 Filing: 000109690615001048 The citation records this snapshot. The page link may show a newer release later.	−USD 7.73 million Exact value Exact value: -7729977 USD 2013-07-01 – 2014-06-30: -7729977 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2014-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Operating Cash Flow: -7729977 USD Concept: fundies:OperatingCashFlow Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3AOperatingCashFlow&period=2014-06-30&surface=latest&period_type=duration&start=2013-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7729977 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690615001048/axn-20150630.xml#34734 Filing: 000109690615001048 The citation records this snapshot. The page link may show a newer release later.	USD 268,922 Exact value Exact value: 268922 USD 2013-07-01 – 2014-06-30: 268922 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AOXING PHARMACEUTICAL COMPANY, INC. · 2014-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Capital Expenditure: 268922 USD Concept: fundies:CapitalExpenditure Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ACapitalExpenditure&period=2014-06-30&surface=latest&period_type=duration&start=2013-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 268922 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690615001048/axn-20150630.xml#35077 Filing: 000109690615001048 The citation records this snapshot. The page link may show a newer release later.	−USD 8 million Calculation and evidence -7729977 − 268922 USD Exact free cash flow: -7998899 USD 2013-07-01 – 2014-06-30: -7729977 USD · Inspect Operating Cash Flow · Source 2013-07-01 – 2014-06-30: 268922 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2014-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Free cash flow: -7998899 USD Concept: free-cash-flow Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7729977 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690615001048/axn-20150630.xml#34734 Filing: 000109690615001048 Input fundies:CapitalExpenditure: 268922 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690615001048/axn-20150630.xml#35077 Filing: 000109690615001048 The citation records this snapshot. The page link may show a newer release later.
2015 2014-07-01 – 2015-06-30	USD 5.49 million Exact value Exact value: 5494713 USD 2014-07-01 – 2015-06-30: 5494713 USD Inspect Net Income Open source Share or cite Citation for Net Income · AOXING PHARMACEUTICAL COMPANY, INC. · 2015-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Net Income: 5494713 USD Concept: fundies:NetIncome Period: 2014-07-01 to 2015-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ANetIncome&period=2015-06-30&surface=latest&period_type=duration&start=2014-07-01&unit=USD&dimensions= Input fundies:NetIncome: 5494713 USD (2014-07-01 to 2015-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#34414 Filing: 000109690616001934 The citation records this snapshot. The page link may show a newer release later.	USD 3.03 million Exact value Exact value: 3025739 USD 2014-07-01 – 2015-06-30: 3025739 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2015-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Operating Cash Flow: 3025739 USD Concept: fundies:OperatingCashFlow Period: 2014-07-01 to 2015-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3AOperatingCashFlow&period=2015-06-30&surface=latest&period_type=duration&start=2014-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 3025739 USD (2014-07-01 to 2015-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#38168 Filing: 000109690616001934 The citation records this snapshot. The page link may show a newer release later.	USD 2.71 million Exact value Exact value: 2705298 USD 2014-07-01 – 2015-06-30: 2705298 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AOXING PHARMACEUTICAL COMPANY, INC. · 2015-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Capital Expenditure: 2705298 USD Concept: fundies:CapitalExpenditure Period: 2014-07-01 to 2015-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ACapitalExpenditure&period=2015-06-30&surface=latest&period_type=duration&start=2014-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2705298 USD (2014-07-01 to 2015-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#38509 Filing: 000109690616001934 The citation records this snapshot. The page link may show a newer release later.	USD 320,441 Calculation and evidence 3025739 − 2705298 USD Exact free cash flow: 320441 USD 2014-07-01 – 2015-06-30: 3025739 USD · Inspect Operating Cash Flow · Source 2014-07-01 – 2015-06-30: 2705298 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2015-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Free cash flow: 320441 USD Concept: free-cash-flow Period: 2014-07-01 to 2015-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 3025739 USD (2014-07-01 to 2015-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#38168 Filing: 000109690616001934 Input fundies:CapitalExpenditure: 2705298 USD (2014-07-01 to 2015-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#38509 Filing: 000109690616001934 The citation records this snapshot. The page link may show a newer release later.
2016 2015-07-01 – 2016-06-30	USD 2.06 million Exact value Exact value: 2061224 USD 2015-07-01 – 2016-06-30: 2061224 USD Inspect Net Income Open source Share or cite Citation for Net Income · AOXING PHARMACEUTICAL COMPANY, INC. · 2016-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Net Income: 2061224 USD Concept: fundies:NetIncome Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ANetIncome&period=2016-06-30&surface=latest&period_type=duration&start=2015-07-01&unit=USD&dimensions= Input fundies:NetIncome: 2061224 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#34301 Filing: 000109690616001934 The citation records this snapshot. The page link may show a newer release later.	−USD 534,990 Exact value Exact value: -534990 USD 2015-07-01 – 2016-06-30: -534990 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2016-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Operating Cash Flow: -534990 USD Concept: fundies:OperatingCashFlow Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3AOperatingCashFlow&period=2016-06-30&surface=latest&period_type=duration&start=2015-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -534990 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#37997 Filing: 000109690616001934 The citation records this snapshot. The page link may show a newer release later.	USD 117,862 Exact value Exact value: 117862 USD 2015-07-01 – 2016-06-30: 117862 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AOXING PHARMACEUTICAL COMPANY, INC. · 2016-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Capital Expenditure: 117862 USD Concept: fundies:CapitalExpenditure Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426/explain?concept=fundies%3ACapitalExpenditure&period=2016-06-30&surface=latest&period_type=duration&start=2015-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 117862 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#38339 Filing: 000109690616001934 The citation records this snapshot. The page link may show a newer release later.	−USD 652,852 Calculation and evidence -534990 − 117862 USD Exact free cash flow: -652852 USD 2015-07-01 – 2016-06-30: -534990 USD · Inspect Operating Cash Flow · Source 2015-07-01 – 2016-06-30: 117862 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AOXING PHARMACEUTICAL COMPANY, INC. · 2016-06-30 AOXING PHARMACEUTICAL COMPANY, INC. (edgar:1060426) Free cash flow: -652852 USD Concept: free-cash-flow Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1060426?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -534990 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#37997 Filing: 000109690616001934 Input fundies:CapitalExpenditure: 117862 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1060426/000109690616001934/axn-20160630.xml#38339 Filing: 000109690616001934 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

100 filings · 1,832 latest values · 1,832 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001060426, 1060426, axn, edgar:1060426

Also known as AOXING PHARMACEUTICAL COMPANY, INC., CENTRAL AMERICAN EQUITIES CORP., CENTRAL AMERICAN EQUITIES INC, CHINA AOXING PHARMACEUTICAL COMPANY, INC.

AOXING PHARMACEUTICAL COMPANY, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2016 2015-07-01 – 2016-06-30

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation